A Phase Ib Study of Combination of Temsirolimus (Torisel) and Pegylated Liposomal Doxorubicin (PLD, Doxil/ Caelyx) in Advanced or Recurrent Breast, Endometrial and Ovarian Cancer.

Trial Profile

A Phase Ib Study of Combination of Temsirolimus (Torisel) and Pegylated Liposomal Doxorubicin (PLD, Doxil/ Caelyx) in Advanced or Recurrent Breast, Endometrial and Ovarian Cancer.

Completed
Phase of Trial: Phase I

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Doxorubicin liposomal (Primary) ; Temsirolimus (Primary)
  • Indications Advanced breast cancer; Endometrial cancer; Ovarian cancer
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 10 Apr 2012 Planned end date changed from 1 Mar 2011 to 1 Aug 2012 as reported by ClinicalTrials.gov.
    • 26 Sep 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top